Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 43 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

8 recruiting

Enrollment Performance

Analytics

N/A
18(41.9%)
Phase 1
14(32.6%)
Early Phase 1
9(20.9%)
Phase 2
2(4.7%)
43Total
N/A(18)
Phase 1(14)
Early Phase 1(9)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (43)

Showing 20 of 43 trials
NCT06874946Phase 1Recruiting

Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

Role: collaborator

NCT06880913Phase 1Recruiting

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Role: collaborator

NCT07435779Early Phase 1Recruiting

Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study

Role: lead

NCT07421856Phase 1Not Yet Recruiting

Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

Role: lead

NCT07234721Early Phase 1Not Yet Recruiting

SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT07244380Phase 2Not Yet Recruiting

Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

Role: lead

NCT07244406Phase 2Recruiting

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

Role: lead

NCT07161193Phase 1Not Yet Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Role: lead

NCT05618041Not ApplicableRecruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Role: lead

NCT05388695Phase 1Recruiting

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

Role: lead

NCT04938115Not ApplicableCompleted

Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

Role: lead

NCT06136364Phase 1Recruiting

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Role: lead

NCT06067581Early Phase 1Unknown

the Safety and Efficacy of SENL103 Autologous T Cell Injection

Role: lead

NCT04916860Not ApplicableUnknown

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Role: lead

NCT05626400Not ApplicableRecruiting

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Role: lead

NCT05619861Not ApplicableUnknown

CAR-T Cells in the Treatment of Malignant Hematological Tumors

Role: lead

NCT05398614Phase 1Unknown

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Role: lead

NCT04928105Not ApplicableUnknown

Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

Role: lead

NCT05388305Not ApplicableUnknown

Universal CAR-γδT Cell Injection in the AML Patients

Role: lead

NCT05333588Early Phase 1Unknown

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Role: lead